Salahuddin T, Kittelson J, Tardif JC, et al. - Researchers determined if there exists a link between HDL particle concentration (HDLP) and the risk of major adverse cardiovascular events (MACE) following acute coronary syndrome (ACS). In patients who encountered a recent ACS, dalcetrapib (CETP inhibitor) was compared with placebo in the dal-Outcomes trial. A nested case-cohort analysis was performed to measure total, large, medium, and small HDLPs using nuclear magnetic resonance spectroscopy at baseline (4-12 weeks post-ACS) in 476 cases with MACE and 902 controls. A median follow-up of 28 months was performed. Findings revealed that neither baseline HDLP nor the alteration in HDLP on therapy with dalcetrapib or placebo was related to the risk of MACE post-ACS.